Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.
Castenmiller SM, Kanagasabesan N, Guislain A, Nicolet BP, van Loenen MM, Monkhorst K, Veenhof AAFA, Smit EF, Hartemink KJ, Haanen JBAG, de Groot R, Wolkers MC. Castenmiller SM, et al. Among authors: de groot r. Oncoimmunology. 2024 Aug 22;13(1):2392898. doi: 10.1080/2162402X.2024.2392898. eCollection 2024. Oncoimmunology. 2024. PMID: 39188755 Free PMC article.
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile.
De Groot R, Van Loenen MM, Guislain A, Nicolet BP, Freen-Van Heeren JJ, Verhagen OJHM, Van Den Heuvel MM, De Jong J, Burger P, Van Der Schoot CE, Spaapen RM, Amsen D, Haanen JBAG, Monkhorst K, Hartemink KJ, Wolkers MC. De Groot R, et al. Among authors: de jong j. Oncoimmunology. 2019 Aug 15;8(11):e1648170. doi: 10.1080/2162402X.2019.1648170. eCollection 2019. Oncoimmunology. 2019. PMID: 31646094 Free PMC article.
T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production.
van Asten SD, de Groot R, van Loenen MM, Castenmiller SM, de Jong J, Monkhorst K, Haanen JBAG, Amsen D, Bex A, Spaapen RM, Wolkers MC. van Asten SD, et al. Among authors: de groot r, de jong j. Oncoimmunology. 2021 Jan 21;10(1):1860482. doi: 10.1080/2162402X.2020.1860482. Oncoimmunology. 2021. PMID: 33537169 Free PMC article.
Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments.
Castenmiller SM, de Groot R, Guislain A, Monkhorst K, Hartemink KJ, Veenhof AAFA, Smit EF, Haanen JBAG, Wolkers MC. Castenmiller SM, et al. Among authors: de groot r. Immunooncol Technol. 2022 Jun 22;15:100090. doi: 10.1016/j.iotech.2022.100090. eCollection 2022 Sep. Immunooncol Technol. 2022. PMID: 35965844 Free PMC article.
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.
Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, van Rooij N, van Leerdam ME, Depla A, Smit EF, Hartemink KJ, de Groot R, Wolkers MC, Sachs N, Snaebjornsson P, Monkhorst K, Haanen J, Clevers H, Schumacher TN, Voest EE. Dijkstra KK, et al. Among authors: de groot r. Cell. 2018 Sep 6;174(6):1586-1598.e12. doi: 10.1016/j.cell.2018.07.009. Epub 2018 Aug 9. Cell. 2018. PMID: 30100188 Free PMC article.
Validation of 70-gene prognosis signature in node-negative breast cancer.
Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ. Bueno-de-Mesquita JM, et al. Among authors: de graaf pw, de groot r. Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26. Breast Cancer Res Treat. 2009. PMID: 18819002
848 results